LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Follow-Up Questions
What is LivaNova PLC (LIVN)'s P/E Ratio?
The P/E ratio of LivaNova PLC is 46.3946
Who is the CEO of LivaNova PLC?
Mr. Vladimir Makatsaria is the Chief Executive Officer of LivaNova PLC, joining the firm since 2024.
What is the price performance of LIVN stock?
The current price of LIVN is $53.73, it has decreased 0% in the last trading day.
What are the primary business themes or industries for LivaNova PLC?
LivaNova PLC belongs to Health Care industry and the sector is Health Care
What is LivaNova PLC market cap?
LivaNova PLC's current market cap is $2.9B
Is LivaNova PLC a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for LivaNova PLC, including 6 strong buy, 7 buy, 3 hold, 0 sell, and 6 strong sell
